Stock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide

Stock Track

Mar 03

ACADIA Pharmaceuticals' stock plummeted 7.37% during intraday trading on Monday, following news of a regulatory setback for its drug candidate.

The decline came after the company announced it received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for trofinetide for the treatment of Rett syndrome. ACADIA stated it plans to request a re-examination of the opinion.

This regulatory hurdle could impact the drug's approval prospects in Europe, leading to investor concerns and the stock's sharp decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1129224909"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129224909\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129224909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129224909","market":"sg","top_or_hot":-1,"title":"Stock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide","media":"Stock Track","content":"<p>ACADIA Pharmaceuticals' stock plummeted 7.37% during intraday trading on Monday, following news of a regulatory setback for its drug candidate.</p><p>The decline came after the company announced it received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for trofinetide for the treatment of Rett syndrome. ACADIA stated it plans to request a re-examination of the opinion.</p><p>This regulatory hurdle could impact the drug's approval prospects in Europe, leading to investor concerns and the stock's sharp decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ACADIA Pharmaceuticals Plummets 7.37% Intraday on Negative CHMP Opinion for Trofinetide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 05:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ACADIA Pharmaceuticals' stock plummeted 7.37% during intraday trading on Monday, following news of a regulatory setback for its drug candidate.</p><p>The decline came after the company announced it received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for trofinetide for the treatment of Rett syndrome. ACADIA stated it plans to request a re-examination of the opinion.</p><p>This regulatory hurdle could impact the drug's approval prospects in Europe, leading to investor concerns and the stock's sharp decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACAD","symbol_name":"阿卡迪亚","start_time":0,"source_url":"","article_id":"1129224909","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129224909","pubTimestamp":1772485643,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ACADIA Pharmaceuticals' stock plummeted 7.37% during intraday trading on Monday, following news of a regulatory setback for its drug candidate.The decline came after the company announced it received...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACAD":"阿卡迪亚"},"translate_title":"个股追踪|阿卡迪亚制药盘中暴跌7.37%因CHMP对Trofinetide的负面意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACAD":1},"content_text":"ACADIA Pharmaceuticals' stock plummeted 7.37% during intraday trading on Monday, following news of a regulatory setback for its drug candidate.The decline came after the company announced it received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for trofinetide for the treatment of Rett syndrome. ACADIA stated it plans to request a re-examination of the opinion.This regulatory hurdle could impact the drug's approval prospects in Europe, leading to investor concerns and the stock's sharp decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}